Articles related to ANTIDEPRESSANTS

The study on the use of subcutaneous racemic ketamine in treatment-resistant depression underscores the significance of a flexible, individualized dosing approach over a 4-week course.

Explore the results of this study, which shed light on the underreported and frequently misunderstood phenomena of “brain zaps” during antidepressant withdrawal and its effects on medicine use and quality of life.

The SSRI inhibitor was previously limited to adults. As physicians, we are continually seeking effective treatment options for our pediatric patients. The recent FDA approval of Lexapro for pediatric GAD treatment marks a significant advancement in this field.

The updated guidelines recommend, in brief:

The analysis found similar benefits for most nonpharmacologic treatments and antidepressants as first-step treatments in MDD. As 1st-line therapy, cognitive behavioral therapies (CBTs) were similar in response to second-generation antidepressants (SGAs) in terms of benefit and remission rates, but discontinuation for adverse events was higher with SGAs. The complementary and alternative medicine interventions St. Johns Wart and acupuncture were also similar to SGAs in terms of response and remission. However, the combination of acupuncture and SGAs yielded higher remission rates. Exercise was also similar to SGAs in remission rates; adding exercise to SGAs gave no added benefit. Antidepressants had a higher risk of discontinuation because of adverse events. For second-step therapies, different switching and augmentation strategies provided similar symptomatic relief.

In an analysis of 26 reviews covering 8 antidepressant classes and 22 pain conditions, no review provided a high level of evidence for the effectiveness of antidepressants for chronic pain. The strongest evidence may be for SNRIs for back pain, postoperative pain, neuropathic pain, and fibromyalgia.